ARL13A Inhibitors
ARL13A Inhibitors primarily target processes and pathways related to vesicular trafficking, cytoskeletal dynamics, and small GTPase function, which are key aspects of ARL13A's role in the cell. Brefeldin A, Nocodazole, and Vinblastine disrupt the structural integrity and function of the Golgi apparatus and microtubules, respectively, potentially impacting processes in which ARL13A is involved. Cytochalasin D's inhibition of actin polymerization and Y-27632, free base's inhibition of ROCK both affect cytoskeletal dynamics, which is relevant to ARL13A's function.
Forskolin, by activating adenylate cyclase, could influence cAMP levels and downstream signaling pathways intersecting with ARL13A's role. ML141 and NSC23766, which inhibit Cdc42 and Rac1 respectively, target small GTPases involved in cytoskeletal organization, a process potentially related to ARL13A. PI3K inhibitors like Wortmannin and LY 294002 could affect signaling pathways that might intersect with ARL13A's function in the cell. Zoledronic acid, anhydrous and Simvastatin, by affecting protein prenylation, could potentially influence the post-translational modification of proteins, including those related to ARL13A's function. These chemicals, while not direct inhibitors of ARL13A, provide various avenues to explore its function through modulation of related cellular processes. Experimental validation is necessary to determine their effectiveness and specificity in this context.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Disrupts Golgi structure and function, potentially affecting ARL13A-related vesicular trafficking. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Destabilizes microtubules, possibly influencing cytoskeletal dynamics related to ARL13A. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $165.00 $486.00 | 64 | |
Inhibits actin polymerization, affecting cytoskeletal arrangements which may intersect with ARL13A function. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $137.00 $512.00 | 7 | |
Inhibits Cdc42, a small GTPase involved in actin organization, relevant to processes influenced by ARL13A. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Inhibits phosphoinositide 3-kinases (PI3Ks), possibly affecting pathways related to ARL13A. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Another PI3K inhibitor, which could influence signaling pathways intersecting with ARL13A's role. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Inhibits ROCK, impacting cytoskeletal dynamics and potentially ARL13A functions. | ||||||
Zoledronic acid, anhydrous | 118072-93-8 | sc-364663 sc-364663A | 25 mg 100 mg | $92.00 $256.00 | 5 | |
Affects prenylation of small GTPases, which could indirectly influence ARL13A. | ||||||
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $31.00 $89.00 $135.00 $443.00 | 13 | |
Inhibit HMG-CoA reductase, affecting protein prenylation and potentially ARL13A-related processes. | ||||||
Vinblastine | 865-21-4 | sc-491749 sc-491749A sc-491749B sc-491749C sc-491749D | 10 mg 50 mg 100 mg 500 mg 1 g | $102.00 $235.00 $459.00 $1749.00 $2958.00 | 4 | |
Disrupts microtubule assembly, possibly affecting ARL13A's role in cellular structure and transport. | ||||||